Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
TARA 
Protara Therapeutics Inc (TARA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: TARA (4-star) is a STRONG-BUY. BUY since 17 days. Simulated Profits (46.05%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $24.2
1 Year Target Price $24.2
| 5 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 339.75% | Avg. Invested days 44 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 206.80M USD | Price to earnings Ratio - | 1Y Target Price 24.2 |
Price to earnings Ratio - | 1Y Target Price 24.2 | ||
Volume (30-day avg) 7 | Beta 1.53 | 52 Weeks Range 1.77 - 6.88 | Updated Date 10/15/2025 |
52 Weeks Range 1.77 - 6.88 | Updated Date 10/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.57 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -27.72% | Return on Equity (TTM) -43.02% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 44547461 | Price to Sales(TTM) - |
Enterprise Value 44547461 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.74 | Shares Outstanding 38581863 | Shares Floating 35462134 |
Shares Outstanding 38581863 | Shares Floating 35462134 | ||
Percent Insiders 2.79 | Percent Institutions 79.57 |
Upturn AI SWOT
Protara Therapeutics Inc
Company Overview
History and Background
Protara Therapeutics Inc. (TARA) is a biopharmaceutical company focused on developing and commercializing transformative therapies for rare diseases. Founded in 2014, it has focused on advancing novel therapeutics and has grown through strategic acquisitions and clinical development progress.
Core Business Areas
- T cell and gene therapies: Protara is focused on the development of cell and gene therapy platforms to target rare pediatric cancers and immune system disorders.
Leadership and Structure
The leadership team consists of experienced executives in biopharmaceuticals, with a structured organizational model typical of development-stage biotech companies. The CEO is Blaine Keller and the CFO is Glenn Drysdale.
Top Products and Market Share
Key Offerings
- TARA-002: TARA-002 is an investigational cell therapy being developed for the treatment of Lymphatic Malformations (LM). The company has not published its current market share or revenue, as it is still in clinical development. Competitors include companies developing other therapies for LM such as sirolimus and other off-label treatments.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive. The demand for rare disease therapies is growing, driven by increased awareness and regulatory incentives.
Positioning
Protara focuses on niche markets within the rare disease space, leveraging its expertise in cell therapies and clinical development. They are a smaller player aiming to address unmet needs.
Total Addressable Market (TAM)
The TAM for rare disease therapies is significant, estimated in the billions of dollars annually. Protara is positioned to capture a portion of this market with successful development and commercialization of its lead product candidate. TAM size varies depending on the exact target disease.
Upturn SWOT Analysis
Strengths
- Focus on rare diseases with unmet needs
- Promising pipeline with TARA-002
- Experienced management team
Weaknesses
- Limited financial resources compared to larger pharma companies
- Reliance on successful clinical trial outcomes
- Early stage of commercialization
Opportunities
- Potential for Orphan Drug designation and expedited regulatory pathways
- Strategic partnerships and collaborations
- Expansion of pipeline through acquisitions or in-licensing
Threats
- Clinical trial failures
- Regulatory hurdles and delays
- Competition from other companies in the rare disease space
Competitors and Market Share
Key Competitors
- BMY
- MRK
- JNJ
Competitive Landscape
Protara faces intense competition from larger pharmaceutical companies with greater resources. Its competitive advantage lies in its focus on specific rare diseases and its expertise in cell therapies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by pipeline development and strategic partnerships. The company has demonstrated the ability to advance its product candidates through clinical trials.
Future Projections: Future growth depends on the successful development and commercialization of TARA-002. Analyst estimates suggest positive revenue growth if TARA-002 gains approval and commercial traction.
Recent Initiatives: Recent initiatives include the advancement of TARA-002 into pivotal clinical trials and efforts to secure additional funding through public offerings and strategic collaborations.
Summary
Protara Therapeutics is a development-stage biotech company focused on rare diseases. Their main asset, TARA-002, holds promise but is still in clinical trials, representing a high-risk, high-reward scenario. They have limited revenue and depend on external funding. The company needs to successfully navigate clinical trials and secure regulatory approval to realize its potential.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Analyst Reports
- Company Website
- Press Releases
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Protara Therapeutics Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2014-10-22 | Co-founder, CEO, President & Director Mr. Jesse Shefferman | ||
Sector Healthcare | Industry Biotechnology | Full time employees 28 | Website https://www.protaratx.com |
Full time employees 28 | Website https://www.protaratx.com | ||
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.